281 related articles for article (PubMed ID: 30374007)
21. Treatment of malignancy-associated hypercalcemia and cachexia with humanized anti-parathyroid hormone-related protein antibody.
Sato K; Onuma E; Yocum RC; Ogata E
Semin Oncol; 2003 Oct; 30(5 Suppl 16):167-73. PubMed ID: 14613038
[TBL] [Abstract][Full Text] [Related]
22. Hypercalcemia and bone resorption in malignancy.
Walls J; Bundred N; Howell A
Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618
[TBL] [Abstract][Full Text] [Related]
23. Mechanisms of cancer-induced hypercalcemia.
Rosol TJ; Capen CC
Lab Invest; 1992 Dec; 67(6):680-702. PubMed ID: 1460860
[TBL] [Abstract][Full Text] [Related]
24. Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia.
Rosner MH; Dalkin AC
Clin J Am Soc Nephrol; 2012 Oct; 7(10):1722-9. PubMed ID: 22879438
[TBL] [Abstract][Full Text] [Related]
25. Bisphosphonate Versus Bisphosphonate and Calcitonin for the Treatment of Moderate to Severe Hypercalcemia of Malignancy.
Khan AA; Gurnani PK; Peksa GD; Whittier WL; DeMott JM
Ann Pharmacother; 2021 Mar; 55(3):277-285. PubMed ID: 32885992
[TBL] [Abstract][Full Text] [Related]
26. Treatment of bisphosphonate-resistant hypercalcemia of malignancy with calcitonin.
Dawson C; Todd AM; Walton A
J Palliat Med; 2014 Oct; 17(10):1084. PubMed ID: 25265187
[No Abstract] [Full Text] [Related]
27. Use of denosumab in parathyroid carcinoma with refractory hypercalcemia.
Tong CV; Hussein Z; Noor NM; Mohamad M; Ng WF
QJM; 2015 Jan; 108(1):49-50. PubMed ID: 25099611
[No Abstract] [Full Text] [Related]
28. Malignant hypercalcemia.
Basso U; Maruzzo M; Roma A; Camozzi V; Luisetto G; Lumachi F
Curr Med Chem; 2011; 18(23):3462-7. PubMed ID: 21756237
[TBL] [Abstract][Full Text] [Related]
29. [Therapeutic possibilities in paraneoplastic hypercalcemia].
Schürer CC; Peters U; Fischer JT
Med Welt; 1981 Aug; 32(32-33):1219-21. PubMed ID: 6456397
[No Abstract] [Full Text] [Related]
30. [Clinical aspects of calcium metabolism disorders of the bone. III. Current topics. 2. Hypercalcemia associated with malignant tumor: progress in the treatment].
Sato K
Nihon Naika Gakkai Zasshi; 1993 Dec; 82(12):2023-7. PubMed ID: 8294802
[No Abstract] [Full Text] [Related]
31. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.
Harinck HI; Bijvoet OL; Plantingh AS; Body JJ; Elte JW; Sleeboom HP; Wildiers J; Neijt JP
Am J Med; 1987 Jun; 82(6):1133-42. PubMed ID: 3300303
[TBL] [Abstract][Full Text] [Related]
32. Denosumab should be the treatment of choice for bisphosphonate refractory hypercalcaemia of malignancy.
Adhikaree J; Newby Y; Sundar S
BMJ Case Rep; 2014 Jan; 2014():. PubMed ID: 24481018
[TBL] [Abstract][Full Text] [Related]
33. [Hypercalcemia in malignancy].
Eto S
Rinsho Byori; 1994 Sep; 42(9):943-51. PubMed ID: 7967119
[TBL] [Abstract][Full Text] [Related]
34. PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab.
Salahudeen AA; Gupta A; Jones JC; Cowan RW; Vusirikala M; Kwong C; Naina HV
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):e137-40. PubMed ID: 26187654
[No Abstract] [Full Text] [Related]
35. The hypercalcemia of malignancy: pathogenesis and management.
Mundy GR; Martin TJ
Metabolism; 1982 Dec; 31(12):1247-77. PubMed ID: 6755168
[TBL] [Abstract][Full Text] [Related]
36. Differences in bone and vitamin D metabolism between primary hyperparathyroidism and malignancy-associated hypercalcemia.
Nakayama K; Fukumoto S; Takeda S; Takeuchi Y; Ishikawa T; Miura M; Hata K; Hane M; Tamura Y; Tanaka Y; Kitaoka M; Obara T; Ogata E; Matsumoto T
J Clin Endocrinol Metab; 1996 Feb; 81(2):607-11. PubMed ID: 8636276
[TBL] [Abstract][Full Text] [Related]
37. [Update on paraneoplastic hypercalcemia. Our experience in the treatment of hypercalcemic states of patients with advanced breast carcinoma].
Grottolo A; Ferrari V; Lazzari R; Mariano MR; Zambruni A; Zaniboni A
Minerva Med; 1988 Jul; 79(7):527-31. PubMed ID: 3405454
[TBL] [Abstract][Full Text] [Related]
38. [A case of esophageal carcinoma with hypercalcemia caused by PTH-rP--the effect of therapy on the bone and calcium metabolism].
Nakayama Y; Okuno S; Miki T; Nishizawa Y; Morii H
Nihon Naibunpi Gakkai Zasshi; 1992 Dec; 68(12):1294-9. PubMed ID: 1291340
[TBL] [Abstract][Full Text] [Related]
39. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
[TBL] [Abstract][Full Text] [Related]
40. Therapeutical approach of hypercalcemia in malignancy.
Duprez D; Rottiers R; Vermeulen A
Acta Clin Belg; 1983; 38(3):165-70. PubMed ID: 6225289
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
